

Forum Review

NADPH Oxidases of the Brain: Distribution, Regulation, and Function

DAVID W. INFANGER,¹ RAM V. SHARMA,^{1,3} and ROBIN L. DAVISSON¹⁻³

ABSTRACT

The NADPH oxidase is a multi-subunit enzyme that catalyzes the reduction of molecular oxygen to form superoxide ($O_2^{\cdot-}$). While classically linked to the respiratory burst in neutrophils, recent evidence now shows that $O_2^{\cdot-}$ (and associated reactive oxygen species, ROS) generated by NADPH oxidase in nonphagocytic cells serves myriad functions in health and disease. An entire new family of NADPH Oxidase (Nox) homologues has emerged, which vary widely in cell and tissue distribution, as well as in function and regulation. A major concept in redox signaling is that while NADPH oxidase-derived ROS are necessary for normal cellular function, excessive oxidative stress can contribute to pathological disease. This certainly is true in the central nervous system (CNS), where normal NADPH oxidase function appears to be required for processes such as neuronal signaling, memory, and central cardiovascular homeostasis, but overproduction of ROS contributes to neurotoxicity, neurodegeneration, and cardiovascular diseases. Despite implications of NADPH oxidase in normal and pathological CNS processes, still relatively little is known about the mechanisms involved. This paper summarizes the evidence for NADPH oxidase distribution, regulation, and function in the CNS, emphasizing the diversity of Nox isoforms and their new and emerging role in neuro-cardiovascular function. In addition, perspectives for future research and novel therapeutic targets are offered. *Antioxid. Redox Signal.* 8, 1583–1596.

INTRODUCTION

THE NADPH OXIDASE is a multi-subunit enzyme that catalyzes the reduction of molecular oxygen and oxidation of NADPH to generate superoxide radicals ($O_2^{\cdot-}$) (5, 53). Originally discovered in polymorphonuclear neutrophils over 4 decades ago, this protein was first shown to provide host defense against bacteria via a rapid respiratory burst of $O_2^{\cdot-}$. The subunits localize in both membrane-bound (cytochrome b_{558} , comprised of p22^{phox} and gp91^{phox}) and cytoplasmic (p40^{phox}, p47^{phox}, and p67^{phox}) locations (5, 53). Upon stimulation, activation of a low-molecular weight G protein (Rac1 or Rac2) and phosphorylation of p47^{phox} initiates migration of the cytosolic elements to the plasma membrane, whereby a functional complex forms that generates $O_2^{\cdot-}$ (5, 38, 53).

Over the last decade, however, the classical paradigm of NADPH oxidase solely as a means to an immunological end has become outdated. As discussed elsewhere in this review series, a vast number of studies have redefined the NADPH oxidase in a wide array of cells and tissues in the context of a diverse set of functions—from mediating normal intracellular signaling to regulating cell growth and death, from modulating inflammatory responses to regulating endothelial function (9, 36, 81). This began with the seminal discovery by Griendling, Lambeth, and colleagues of a gp91^{phox} homologue in a nonphagocytic cell type named NADPH oxidase 1 (Nox1). Their discovery of Nox1 in vascular smooth muscle cells, along with its critical role in cell growth regulation (93), rapidly spurred an enormous amount of research on this enzyme complex. We now know there is an entire family of

¹Department of Anatomy and Cell Biology, Free Radical and Radiation Biology Program, ²Department of Radiation Oncology, and ³The Cardiovascular Center Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa.

Nox proteins: Nox1, gp91^{phox} (Nox2), Nox3, Nox4, Nox5, and Dual Oxidase 1 and 2 (Duox1 and Duox2) (9, 36, 53). In conjunction with p22^{phox}, the Nox homologues are considered to be the catalytic component from which NADPH oxidase derives its functional capacity, since this subunit facilitates electron transfer by interacting with heme, NADPH, and flavin adenine dinucleotide elements (53). Whereas close structural and functional similarities exist between the different homologues, each is diversely expressed and regulated across distinct tissue and cell types (6, 9, 36, 53, 54, 62). Importantly, multiple Nox isoforms can coexist within an individual cell and can serve distinct cellular functions (36, 54), thus increasing the complexity of regulation of the oxidative environment. Additional complexity arises due to the fact that O₂^{•-} can be further reduced to produce additional reactive oxygen species (ROS, such as hydrogen peroxide [H₂O₂] and hydroxyl radicals [OH⁻]). While oxidative levels are normally kept in check by endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase, these enzymes (*e.g.*, SOD) can generate new ROS which can also participate in intracellular redox signaling.

The focus of this review will be on the expression, regulation, and function of NADPH oxidase and redox mechanisms in the brain. Given the enormous diversity of central nervous system (CNS) function—from coordinating body movement to interpreting senses, controlling behavior, establishing memory, and regulating cardiovascular homeostasis—understanding a complex enzyme such as NADPH oxidase in the CNS poses a considerable challenge. However, exciting new evidence demonstrating the importance of Nox enzymes in normal neuronal function and in CNS diseases has recently begun to emerge. For example, it is becoming increasingly clear that many of the neurodegenerative diseases of the CNS arise from a common defect, namely excessive free radical levels in particular brain regions. So-called oxidative stress—due to augmented production of ROS and/or decreased antioxidant capacity of cells to detoxify these molecules—is involved in Parkinson's and Alzheimer's diseases (11, 43, 85). This has prompted investigations into the basis of ROS production, and the NADPH oxidase complex has emerged as an important potential source of ROS generation in the neuronal cell death that characterizes these diseases (98, 113). Another important CNS function where oxidant mechanisms and NADPH oxidase are now known to be critical is the central neural regulation of the cardiovascular system. For example, angiotensin II (Ang-II), a well-known peptide that regulates central sympathetic outflow, vasopressin release, and fluid homeostasis, ultimately impacting blood pressure, cardiac function, and renal physiology, has been shown to do so in part via ROS/NADPH oxidase mechanisms (59, 119, 120). Furthermore, dysregulation of these central redox pathways, including the NADPH subunits, is now strongly implicated in hypertension (121) and heart failure (30, 56).

The tremendous potential importance of NADPH oxidase in the CNS, coupled with a keen appreciation of the complexity of this enzyme family, provides the impetus for this review. Here we will summarize our current understanding of this complex in the brain, highlighting the expression patterns and differential functional roles of the homologues and subunits. We will be relatively brief in discussing NADPH

oxidase in the context of memory, neurodegenerative pathologies, and ischemic cerebral vessel injury since these topics have been reviewed elsewhere (67, 74, 99, 113). Instead, we will focus more on the recent and growing body of evidence suggesting a pivotal role for the NADPH oxidase as a mediator of central neuro-cardiovascular function and disease.

NADPH OXIDASE DISTRIBUTION AND FUNCTION IN NONCARDIOVASCULAR REGIONS OF THE CNS

Despite increasing evidence for redox signaling and NADPH oxidase in normal CNS processes, as well as a number of brain diseases (85, 113), still relatively little is known about the expression, regulation, and function of this enzyme complex in cerebral cells or tissues. As in the periphery, the dearth of easily available specific antibodies, especially for the Nox homologues, and a lack of tissue and/or cell type-specific knockout animal models or other gene silencing strategies have slowed progress. Nonetheless, new advances have been made and considerable evidence has accumulated that definitively establish an important role for NADPH oxidase in the CNS. We begin here with a summary of what is known about its distribution in the brain.

Spatial localization of NADPH oxidase subunits

One of the first demonstrations of NADPH oxidase in neural cells was a study by Tammariello *et al.* (98). In this study they showed that all the classical subunits of the Nox2 enzyme were expressed in rat isolated sympathetic neuron cultures, which were necessary to generate O₂^{•-} and stimulate programmed cell death in the absence of nerve growth factor. Since then, immunohistochemical approaches in rat (46) and mouse (88) brain samples have been instrumental in determining localization of NADPH oxidase subunits in different regions of the CNS. Serrano *et al.*, using polyclonal antibodies to p40^{phox}, p47^{phox}, and p67^{phox}, p22^{phox}, and Nox2, demonstrated widespread expression of each of these five proteins separately in serial microsections of mouse fore-, mid-, and hindbrain (88). The staining was most prominent in neurons of the hippocampus, cortex, amygdala, striatum, and thalamus. Although immunostaining for the cytoplasmic subunits was diffuse throughout the cell, membrane-associated p22^{phox} and Nox2 exhibited punctate staining, suggestive of a traditional subcellular localization of these subunits. In rat, there was also strong neuronal immunoreactivity for p47^{phox} and Nox2 in regions of hippocampus and cerebral cortex; however, these authors observed little or no staining for these subunits in thalamus, brainstem, or amygdala (46). Likewise, rat cerebellar and hypothalamic neurons also showed NADPH oxidase immunoreactivity, whereas corresponding mouse tissues did not (46, 88). Some of the differences seen between these two immunohistochemical studies are likely due to different antibodies and staining methods used.

Interestingly, neither of these studies detected NADPH oxidase subunits in microglia, which function as resident immune cells of the CNS (24). This finding is surprising, since microglia have been shown to generate NADPH oxidase-derived

$O_2^{\cdot-}$ in response to phorbol ester stimulation (60, 84). In addition, mRNA transcripts of all the classical phagocytic subunits have been detected in isolated fetal human microglia, and p22^{phox}, p47^{phox}, and Nox2 proteins have been detected by immunostaining in perivascular cells in rats (34). Furthermore, microglia from p47^{phox}-mutant mice are unable to initiate an oxidative response to phorbol ester; however, this response can be restored with retroviral transduction of the p47^{phox} gene (55). Taken together, these results strongly suggest NADPH oxidase-dependent $O_2^{\cdot-}$ production in microglia. As described in more detail below, microglial Nox2 also appears to play a prominent role in Parkinson's disease pathology.

In addition to Nox2, recent studies have detected other Nox isoforms in cerebral tissue as well. Cheng *et al.* (16) have detected low levels of Nox4 and Nox5 expression in adult human brain tissue. Interestingly, fetal human brain tissue shows robust Nox4 and Nox5 expression as well as low levels of Nox1, suggesting a role for these homologues in early development. In support of this, Nox4 expression has also been detected in cortical neurons and newly-formed cerebral capillaries after ischemia (103). In addition, a recent study using degenerate PCR primers detected Nox1, Nox3, and Duox1 expression at low levels in rat brain tissue (63). Given the current lack of cellular resolution, it is difficult to speculate on the function of these Nox isoforms in specific neuronal circuits or locations.

NADPH oxidase in hippocampal-dependent memory

The pronounced immunostaining of NADPH oxidase subunits in regions of mouse and rat hippocampus described above suggests that the intracellular redox environment may be important for normal cellular processes of these neurons, such as long-term potentiation (LTP) and hippocampus-dependent memory. Indeed, $O_2^{\cdot-}$ has been strongly implicated in LTP in mice, since transgenic models overexpressing extracellular SOD (EC-SOD) show impaired memory function which can be reversed through pharmacological inhibitors to the enzyme (100). Furthermore, neuron–glia signaling in the hippocampus has been shown to generate ROS, which can impact post-translational modifications in neighboring cells and enhance LTP (3). A role for NADPH oxidase in LTP and memory is also supported by the recent detection of enzyme subunits p22^{phox}, Nox2, p47^{phox}, and p67^{phox} at synaptic sites in hippocampal neurons, which were further shown to assemble and generate $O_2^{\cdot-}$ when stimulated with phorbol ester (99).

It is important to note that while intracellular redox signaling—in part due to NADPH oxidase function—appears necessary for normal LTP and memory functions of hippocampal neurons, excessive oxidative stress can also impair cellular processes and even lead to neuronal death (Fig. 1). For example, hydrogen peroxide, a product of $O_2^{\cdot-}$ dismutation, has been shown to inhibit LTP in rat hippocampal slices (4). Furthermore, excessive $O_2^{\cdot-}$ generation imparted by NADPH oxidase activation contributes to hippocampal neuronal death in chemically-induced seizures in rats (75). Interestingly, this chemically-induced neuronal death was exacerbated in EC-SOD knockout mice, while transgenic animals overexpressing EC-SOD were protected (75). Taken together, these findings suggest that normal neuronal functions of the hippocampus—




FIG. 1. Normal CNS function depends on a balanced oxidant environment. Hippocampal processes, such as long-term potentiation and memory, are inhibited in mice in which basal ROS levels are reduced by scavengers. On the other hand, excessive production of oxidant radicals is linked to improper neuronal signaling in this and other brain regions, and in some instances can lead to neuronal cell death. Neurodegenerative diseases such as Alzheimer's and Parkinson's are characterized by increased oxidative stress, lipid, protein, and DNA oxidation, and neuronal cell death in brain regions associated with these diseases. More recently, NADPH oxidase upregulation and activation in both neurons and microglia has emerged as an important mechanism of oxidative stress in CNS.

LTP and memory—rely on a carefully modulated redox environment and can be impaired by both lack of as well as overproduction of ROS (Fig. 1).

NADPH oxidase in neurodegenerative diseases

The importance of uncontrolled ROS production in mediating cellular pathology, described in Figure 1, also serves as a good paradigm for neurodegenerative diseases. For example, chronic oxidative stress has been implicated in neuronal cell death, protein aggregations, and the pathogenesis of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases (33, 50, 72). Despite the established link between chronic ROS overproduction and pathological neurodegeneration, the source of ROS and the cell type involved remains unknown. While mitochondrial dysfunction can lead to increased oxidative stress in neurons and glia (85), a growing body of evidence supports a role for abnormal NADPH oxidase activation in these pro-oxidative conditions. For example, post-mortem brain tissue from Alzheimer's disease patients exhibits an increased accumulation of cytosolic NADPH oxidase subunits p47^{phox} and p67^{phox} at the cell surface of diseased brain regions, suggesting chronic activation of this complex (89). Moreover, addition of β -amyloid fragments derived from Alzheimer's patients to cultured primary rat microglial cells has been shown to elicit $O_2^{\cdot-}$ generation via an NADPH oxidase-dependent mechanism (7). Increased $O_2^{\cdot-}$ generation and subsequent H_2O_2 formation resulting from β -amyloid-stimulated NADPH oxidase activates neutral sphingomyelinase in neuronal cells, which may promote neuronal apoptosis in the diseased areas (42). Although the mechanisms of persistent NADPH oxidase activation are not completely understood, it has been suggested that blood-derived factors often observed in Alzheimer's brains (8), presumably from a compromised blood–brain barrier, may be involved in NADPH oxidase activation and neuronal apoptosis. In support of this, Choi *et al.* (17) have

shown that cerebral injection of thrombin, one such blood-derived factor, elicits Nox2, p47^{phox}, and p67^{phox} upregulation in rat microglia, as well as NADPH oxidase assembly at the cell surface. Importantly, they showed that thrombin-induced neuronal apoptosis could be prevented by NADPH oxidase inhibitors, further implicating this complex in the neurodegenerative process. As summarized in Fig. 1, these studies clearly link NADPH oxidase-derived ROS with protein oxidation, aggregation, and neuronal death in Alzheimer's disease; however the specific molecules, cell types, and mechanisms remain to be elucidated.

Similarly, new evidence suggests abnormal NADPH oxidase function in the pathogenesis of Parkinson's disease, although the underlying mechanisms are incompletely understood. This syndrome, characterized by degeneration of dopaminergic neurons of the zona compacta of substantia nigra (73), exhibits high levels of oxidative damage to the neuronal milieu of this region. Using dopaminergic-specific neurotoxins to model the disease process, a critical role for oxidative stress imparted by microglial NADPH oxidase has been elucidated. Gao *et al.* (28) isolated primary mesencephalic neurons and associated microglia from Nox2 knock-out mice to test the hypothesis that this Nox homologue is an important source of O₂^{•-} generation during rotenone-induced dopaminergic neuron degeneration. In this study, normal cultured dopaminergic neurons co-cultured with microglia from the knock-out mice were more resistant to rotenone-induced neurotoxicity, as compared to wild-type cultures. On the other hand, purified dopaminergic neuronal cultures from the knock-out mice were more susceptible to rotenone-induced cell death when mixed with Nox2-containing microglia, further underscoring the potential importance of Nox2 activation in these cells in mediating the effects of the neurotoxin. Nox2 knock-out models have also been used to establish NADPH oxidase dysfunction in other models of Parkinson's disease, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced degeneration of dopamine-specific neurons (29). More recently, the neuroprotective effects of dextromethorphan in an *in vivo* MPTP model of Parkinson's disease have been linked to microglial NADPH oxidase inhibition (116). Collectively, these findings provide convincing evidence for microglial NADPH oxidase-derived oxidative stress in Parkinson's disease (Fig. 1).

NADPH oxidase in cerebral ischemic injury

Another CNS disorder in which oxidative stress is well established as a key player is cerebral ischemia (51, 74). Walder *et al.* (104) were the first to show a pivotal role for NADPH oxidase-derived O₂^{•-} generation in ischemic stroke injury. Using Nox2 knockout mice, they demonstrated that brain injury in response to middle cerebral artery occlusion (MCAO) was markedly attenuated in mice lacking functional NADPH oxidase. Similarly, several recent reports have shown protection against hypoxia/reperfusion-induced brain infarctions in Nox2 knockout mice (41, 114). In further support of this, Kusaka *et al.* (52) reported that focal cerebral ischemia induced by MCAO/reperfusion was accompanied by an increase in the Nox2 and p22^{phox} mRNA levels in the ipsilateral hemisphere, and this increase was further augmented in diabetic rats. Using the Ang-II AT-1 receptor inhibitor candesartan, their results further demonstrated that ischemia/reperfusion-induced cere-

bral infarction and NADPH oxidase induction was mediated by Ang-II-AT-1 receptor-dependent pathways.

In addition to the crucial role of Nox2, recent efforts also suggest involvement of Nox4-containing NADPH oxidase in experimental brain ischemia. For example, Vallet *et al.* (103) have shown Nox4 expression in selective populations of neurons located in brain areas susceptible to ischemic damage. Further, these investigators demonstrated that Nox4 expression is increased in infarcted brain tissue five-fold 1–2 weeks after ischemia/reperfusion injury. In addition, Nox4 expression is observed in rat basilar and middle cerebral arteries (68, 74), as well as endothelial cells isolated from rat basilar artery (1). Interestingly, expression of Nox4 and ROS production is 10–100 times more in cerebral arteries as compared to peripheral vessels (68), and it has been suggested that Nox4-derived ROS may play a critical role in the regulation of cerebral vascular tone under physiological conditions. In addition, using immunohistochemical localization of Nox4, Vallet *et al.* (103) have shown that its expression is markedly increased in newly-formed capillaries in the peri-infarct zone of ischemia-injured brain tissue, and have suggested that Nox4 oxidase-derived ROS may promote vasculogenesis in the ischemic zone.

These findings are particularly interesting in light of a recent study by Martyn *et al.* (62). These authors have shown that transfection of Nox4 into HEK293 cells results in constitutive production of H₂O₂ rather than O₂^{•-}, and that Nox4, in conjunction with p22^{phox}, does not require cytosolic proteins p47^{phox} or p67^{phox} for activation. One possibility is that constitutive activation of Nox4-containing NADPH oxidase could account for the markedly higher concentrations of ROS observed in cerebral arteries compared to peripheral vessels (68). Interestingly, H₂O₂ has been shown to function as a vasodilator in rat cerebral arteries via opening of calcium channels in vascular smooth muscle cells (74), and pretreatment with catalase has been shown to abolish the vasodilating effect of NADPH oxidase activation (74). It is intriguing to speculate if NADPH oxidase-mediated vasodilatation in cerebral vessels may in part occur via constitutive production of H₂O₂ from a Nox4-containing complex.

Taken together, these studies implicate both Nox2 and Nox4-containing NADPH oxidases in the pathophysiology of ischemia/reperfusion-induced neuronal injury and subsequent vessel replacement. However, it remains to be seen whether specific neuronal and vessel populations differentially express Nox2 and Nox4, and whether these enzymes are expressed and activated in microglia during ischemic stroke. Similarly, defining the relative contribution of neuronal versus vascular Nox2 and Nox4 in the pathophysiology of stroke will require further studies, since these enzymes are implicated in both normal cerebral vascular physiology (68), and pathology of neurovascular diseases (44, 110).

THE CNS AS A POTENT REGULATOR OF CARDIOVASCULAR FUNCTION

The CNS exerts a profound influence on the cardiovascular system to maintain control of blood pressure, volume balance, and cardiac function. It receives, processes, and inte-

grates a host of neural and humoral signals that reflect the cardiovascular status of the organism, and orchestrates appropriate effector systems (e.g., autonomic nerves and neurohormones) to maintain homeostasis. In fact, most cardiovascular diseases involve some type of dysfunction in CNS mechanisms. For example, many humans with chronic hypertension exhibit exaggerated sympathetic nervous system activity (26). Likewise, chronic heart failure is characterized by augmented sympathetic nerve function, baroreflex function, and abnormal hormone mechanisms, and the most effective treatments to improve survival in patients target pathological neurohumoral excitation (27). Emerging evidence also suggests overactivity of the CNS in metabolic disorders known to be major risk factors for cardiovascular disease, including diabetes and obesity (79). In spite of the critical role of the CNS in controlling cardiovascular balance and mediating cardiovascular pathology, surprisingly little is known about the molecular substrates of the central neural pathways involved.

A host of central and peripheral factors contribute to the pathogenic function of CNS mechanisms in cardiovascular disease. Of these, Ang-II has emerged as a key player (20). It has long been known that injection of Ang-II directly in specific brain regions inside the blood-brain barrier (BBB) elicits profound blood pressure, heart rate, and dipsogenic responses, suggesting the evidence of Ang-II processing systems in the CNS (61). Since then, all of the substrates and enzymes necessary for Ang-II production and responses (e.g., Ang-II receptors, AT-1 and AT-2) have been identified in the brain (83), and it is well established that Ang-II functions as a neurotransmitter/neuromodulator in cardiovascular regulatory circuits (20). Evidence that overactivation of brain Ang-II signaling leads to hypertension and related diseases further underscores the importance of this peptidergic system in neurocardiovascular regulation (20).

In addition to its role inside the CNS, Ang-II is also a major factor in the systemic circulation that signals blood pressure and fluid status to the CNS. However, since the CNS is largely isolated from blood-borne peptides such as Ang-II because it is too large to cross the BBB, communication between the circulation and the CNS takes place at specialized brain regions lacking such a barrier, termed circumventricular organs (CVOs) (20). These CVOs, including the subfornical organ (SFO) and organum vasculosum of the lamina terminalis (OVLT) in the forebrain, contain high concentrations of AT-1 receptors that bind circulating Ang-II (20). This stimulates downstream circuits in the brain, ultimately leading to CNS effector pathway activation and neurocardiovascular responses. For example, blood-borne Ang-II acting at the SFO subsequently leads to stimulation of the paraventricular nucleus (PVN) (66). The PVN, in turn, sends excitatory projections to the sympathetic premotor neurons in the rostral ventrolateral medulla (RVLM), ultimately causing increased sympathetic outflow (45). Activation of the PVN is also involved in the synthesis and release of vasopressin. Additionally, high concentrations of AT-1 receptors have been detected in the hindbrain CVO region area postrema (AP) (22). Ang-II binds these neurons, which send projections to neurons of the nucleus tractus solitarius (NTS) and RVLM, also rich in AT-1 receptors (95), which in turn synapse upon preganglionic neurons of the spinal cord (39). Collectively, these and other neuronal circuits relay signals derived from the circulation and other peripheral sites and

couple them with networks involved in maintaining cardiovascular homeostasis.

NADPH OXIDASE AND Ang-II SIGNALING IN THE CNS

Abundant research now suggests that a key mechanism through which Ang-II influences blood pressure and other cardiovascular endpoints is via its ability to activate ROS signaling pathways. It has been over a decade now since Harrison, Griendling, and colleagues first discovered that Ang-II activates an NADPH oxidase in vascular smooth muscle cells (37, 80). This launched a new field from which a critical concept in cardiovascular physiology emerged: that ROS are pivotal primary effectors in a variety of Ang-II-mediated processes in cardiovascular cells, and that dysregulation of redox mechanisms are strongly implicated in cardiovascular diseases such as hypertension, atherosclerosis, and heart failure (9, 36, 81). More recently, accumulating evidence from our laboratory and others suggests that, like peripheral cardiovascular cells, neurocardiovascular cells of the CNS also require ROS to carry out crucial functions related to central control of blood pressure and other cardiovascular parameters (118).

In 2002, we made the observation that $O_2^{\cdot-}$ was necessary to elicit the vasopressor, bradycardiac, and dipsogenic responses produced by intracerebroventricular (ICV) administration of Ang-II in conscious mice (120). Using recombinant viral vectors to target human SOD transgenes selectively to forebrain CVOs in a highly robust and stable manner (91), our studies showed that scavenging $O_2^{\cdot-}$ in this brain region completely abolished the cardiovascular and dipsogenic actions of Ang-II. Importantly, these studies also demonstrated that the requirement for $O_2^{\cdot-}$ was specific to Ang-II since the pressor response to another central pressor agent, the muscarinic agonist carbachol, was completely intact in SOD-treated mice (120). Finally, we also provided direct evidence in these studies that Ang-II causes robust increases in $O_2^{\cdot-}$ production in cultured CNS neurons from this forebrain CVO area.

While it is known that the increase in blood pressure caused by central Ang-II involves sympathoexcitation, our studies did not address this directly. Recent work by several groups has provided important evidence linking central Ang-II, ROS, and sympathoexcitation. CNS administration of the SOD mimetic Tempol or PEG-encapsulated SOD attenuated ICV Ang-II-induced increases in renal sympathetic nerve activity (RSNA), norepinephrine secretion, and blood pressure (12, 13, 59). Similarly, bilateral microinjection of Tempol directly into RVLM has been shown to inhibit Ang-II-induced increases in blood pressure, tachycardia, and renal sympathoexcitation, suggesting a role for ROS in excitatory responses of Ang-II in RVLM (65). These recent findings on the involvement of ROS in sympathetic activity are interesting in light of studies from 5 years ago by Zanzinger that showed direct administration of SOD into RVLM inhibits RSNA in pigs chronically subjected to oxidative stress by long-term treatment with organic nitrates (112).

While ROS generation has proven necessary to mediate the *in vivo* effects of Ang-II signaling in CNS cardiovascular circuits, only recently has the source of these free radicals been

investigated. Using adenovirus-mediated gene transfer of a dominant-negative mutant of Rac1 (AdN17Rac1), a cofactor essential for NADPH oxidase assembly and activation (35), we have recently demonstrated a requirement for NADPH oxidase in Ang-II-stimulated ROS generation in primary neurons derived from the forebrain lamina terminalis, a region that encompasses the CVOs (119). More importantly, inhibition of NADPH oxidase assembly by AdN17Rac1 resulted in complete loss of pressor, bradycardiac, and dipsogenic responses to Ang-II, further underscoring the importance of ROS—and the NADPH oxidase complex—in this signaling cascade.

Although the studies described above implicate NADPH oxidase-derived $O_2^{\cdot-}$ in Ang-II-induced signaling in cardiovascular nuclei in the CNS, the downstream mechanisms of ROS-mediated neuronal activation are incompletely understood. Recent evidence suggests that ROS may enhance neuronal activation by increases in intracellular calcium. For example, Wang *et al.* (105) utilized a double-label immunoelectron microscopy approach to demonstrate co-localization of the Nox2 subunit of NADPH oxidase with AT-1 receptors in dorsomedial neurons of the NTS. Further, these investigators demonstrated that inhibition of this complex via the pharmacological inhibitor of NADPH oxidase apocynin or an inhibitory Nox2 peptide docking sequence (gp91-ds-tat) (82) decreased Ang-II-stimulated increases in cytosolic calcium and neuronal potentiation. Similarly, we have shown that treatment with Ang-II produces a rapid influx of calcium into neuronal cells, and that this response was abolished by overexpression of the dominant-negative AdN17Rac1 or AdCuZnSOD, thereby implicating an active NADPH oxidase-derived $O_2^{\cdot-}$ in this signaling pathway (122). These findings were later confirmed by Sun *et al.* through the use of pharmacological and peptide inhibitors of NADPH oxidase (94). Importantly, these investigators also provided evidence for a critical link between Nox2 and Ang-II in neuronal firing, and further implicated a role for the active complex in inhibiting a delayed rectifier potassium channel in these neurons (94).

A recent elegant study by Chan *et al.* (14) has further advanced our understanding of Ang-II/NADPH oxidase signaling mechanisms in central cardiovascular neurons. They showed that bilateral Ang-II injections into the RVLM increases NADPH oxidase activation, $O_2^{\cdot-}$ generation, and stimulates the mitogen-activated protein kinase (MAPK) signaling cascade. Ang-II caused phosphorylation of p38 MAPK as well as extracellular signal-related protein kinase 1/2 (ERK 1/2) in RVLM, and this could be inhibited by co-injection of pharmacological inhibitors of the AT-1 receptor or the NADPH oxidase, as well as Tempol or antisense oligonucleotides targeted to NADPH subunits. Furthermore, addition of a MAPK phosphorylation inhibitor significantly attenuated Ang-II-stimulated pressor responses from the RVLM, as well as abolished the frequency of glutamate-sensitive postsynaptic excitatory currents. These findings strongly suggest that redox activation of MAPK signaling is involved in the sympathoexcitatory effect of Ang-II, possibly through the stimulated release of glutamate from presynaptic neurons at the RVLM.

Together, these studies provide clear evidence that intracellular $O_2^{\cdot-}$ generation is required for activation of cardiovascular neurons, at least in some brain regions, in response to Ang-II. The mechanisms by which Ang-II activates NADPH oxidase in neurons, and how subsequent $O_2^{\cdot-}$ signals to cause

changes in neurohumoral responses and regulation of cardiovascular function is an area of intense investigation in several laboratories, including ours. Elucidating these pathways will advance our understanding of neurocardiovascular regulation.

NADPH OXIDASE IN CENTRAL NEUROCARDIOVASCULAR DISEASES

Hypertension

The evidence that human hypertension is characterized by dysfunction of central neural pathways is now extremely compelling (23). Ang-II has emerged as a primary culprit, driving central neurohumoral abnormalities in hypertension, although the precise molecular mechanisms and physiological circuits remain largely unknown.

As discussed above, abundant evidence now points to oxidative stress as a key mechanism in Ang-II-dependent hypertension and other diseases in the periphery. Furthermore, it has become clear that ROS are important in the pressor effects of Ang-II administered directly in the CNS. Recently we tested the hypothesis that hypertension caused by elevated circulating Ang-II might also involve an increase in intracellular $O_2^{\cdot-}$ levels in CNS neurons (121). Using chronic systemic infusion of subpressor doses of Ang-II, the so-called “slow-pressor” model of hypertension in mice [which closely mimics human hypertension (25)], we observed marked increase in $O_2^{\cdot-}$ production selectively in the forebrain CVO, SFO. Importantly, this increase in $O_2^{\cdot-}$ radical production paralleled the increase in MAP and reached a maximum on day 16, the time of peak hypertension. Both the oxidant production in SFO and the hypertension were abolished in mice that had received ICV delivery of a recombinant adenovirus expressing CuZnSOD, clearly demonstrating the requirement of $O_2^{\cdot-}$ in this vasopressor response. Interestingly, viral gene transfer of EC-SOD neither reduced ROS in the SFO nor affected hypertension, demonstrating that Ang-II effects are mediated by intracellular but not extracellular $O_2^{\cdot-}$ generation in neurons. These results suggest that Ang-II-induced increases in $O_2^{\cdot-}$ production in SFO plays a key role in the development of hypertension. Interestingly, recent results from Raizada’s group (87) have demonstrated that soluble epoxide-mediated blood pressure regulation in the spontaneously hypertensive rat (SHR) is mediated by NADPH oxidase-derived $O_2^{\cdot-}$ generation in forebrain CVOs, further supporting an important role for ROS signaling in these regions in hypertension.

The hypothesis that chronic increases in ROS production in the CNS is involved in neurogenic hypertension is further supported by recent studies demonstrating increased levels of ROS in RVLM of SHR rats, as compared to Wistar-Kyoto (WKY) rats (49). Importantly, bilateral microinjection of SOD mimetics into RVLM or overexpression of MnSOD decreased both blood pressure and sympathetic nerve activity in SHR but not WKY rats (49, 97). Furthermore, chronic increases in ROS levels in normotensive WKY rat RVLM by Ad-mediated overexpression of inducible-NOS (iNOS) enzyme produced hypertension which was abrogated by bilateral microinjection of Tempol (47). Together these studies underscore the importance of chronic increase in ROS levels in key cardiovascular regulatory nuclei in the brain in neurogenic hypertension.

Ang-II-stimulated increases in ROS may also act by compromising sympathoinhibitory mechanisms in the CNS as well, thereby contributing to hypertension. The NTS and RVLM have been shown to generate nitric oxide (NO), which decreases sympathetic activity and depresses blood pressure (111). Whereas transgenic mice lacking endothelial nitric oxide synthase (eNOS) develop hypertension (40), viral delivery of eNOS selectively into the NTS causes a significant decrease in blood pressure in spontaneously hypertensive rats (96). Since $O_2^{\cdot-}$ can react with NO, thereby producing peroxynitrite and reducing NO concentrations, it is postulated that reductions in NO-mediated sympathoinhibition by this mechanism may play an important role in hypertension.

These findings, along with studies discussed above demonstrating a requirement for a Rac1-dependent NADPH oxidase in forebrain Ang-II signaling (119), suggest the involvement of this enzyme complex in cardiovascular regulation mediated by this region. Interestingly, expression of NADPH oxidase complex proteins has also recently been observed in brainstem cardiovascular regulatory nuclei of the CNS. Zucker and colleagues showed expression of Nox2, p40^{phox}, p47^{phox}, and p67^{phox} in RVLM of rabbits, and levels of all these proteins were increased by ICV Ang-II injection (30, 32). Similarly, Chan *et al.* have demonstrated the presence of Nox2, p22^{phox}, p47^{phox}, and p67^{phox} mRNA in rat RVLM, and importantly, Ang-II increased the serine phosphorylation of p47^{phox}, suggesting an increase in NADPH oxidase assembly and activation (14). Furthermore, bilateral injection of antisense oligonucleotides directed against either p22^{phox} or p47^{phox} inhibited Ang-II-induced $O_2^{\cdot-}$ production, clearly demonstrating the involvement of Nox2 NADPH oxidase in Ang-II signaling in RVLM (14). Importantly, Nox2 immunoreactivity has been observed in other central sites of Ang-II-mediated autonomic regulation, including the NTS (105) and PVN (46).

In contrast to the above findings, a recent study by Touyz *et al.* using double transgenic mice in which Nox2 is deleted and the endogenous renin-angiotensin system is chronically upregulated [including the brain RAS (78)], has suggested that loss of functional Nox2 does not prevent development of hypertension and cardiac hypertrophy in this model (102). In this study, while the double-transgenic progeny exhibited significantly reduced ROS levels in cardiac, aortic, and renal tissues compared to control single transgenic mice overexpressing renin, these animals still developed chronic Ang-II-dependent hypertension. Importantly, compensatory increases in Nox1 and Nox4 expression were not observed in cardiac and renal tissues of the double Nox2 knockout/renin overexpressing mice, raising questions about the links between Ang-II, ROS, and hypertension. Although it is not clear at this time, an intriguing possibility is that increased circulating Ang-II may be producing hypertension in this model by neurogenic mechanisms as described above (121). As such, the hypertension and related sequelae observed in this model may still be the result of ROS, but working through compensatory increases in expression of other Nox homologues within the CNS in this model.

Sympathetic activation in heart failure

Dysregulation of autonomic function—including a persistent overactivation of the sympathetic nervous system—is

well established in the etiology of chronic heart failure (HF) (27). Cardiac ventricular impairment, initiated by any of a number of pathological states, elicits the release of various neurohumoral substances including Ang-II into the circulation and from peripheral organs, which collectively contribute to the maintenance of tissue perfusion and arterial pressure via vasoconstriction, increased blood volume, enhanced heart rate, and augmented neurocardiovascular output (27, 123). While these compensatory mechanisms are beneficial in the short-term, chronic neurohumoral activation contributes to the deterioration of myocardial function over time (123).

During HF, blood-borne factors, such as Ang-II, are increased (107). Elevated Ang-II, for example, is in constant contact with forebrain and hindbrain CVOs via AT-1 receptors, which in turn can stimulate sympathetic nerve activity as described above (22). Enhanced sympathetic activity has widespread effects, including promotion of excess sodium retention and therefore fluid volume, leading to edema, lung congestion, and cardiac stress (108). Direct effects of excessive sympathetic effects on the heart are also a factor. Evidence for a critical role of the CNS in driving this neurohumoral state comes from experiments in which coronary artery ligation (myocardial infarction, MI) induced impairment of arterial baroreflex control of heart rate, and RSNA were ameliorated by chronic ICV infusion of AT-1 inhibitor losartan (115). Similarly, microinjection of antisense oligodeoxynucleotides to the AT-1 receptor in PVN has been shown to blunt resting sympathetic activity in CHF rats, once again implicating increased central Ang-II signaling in the neurohumoral response during HF (117).

Given the involvement of Ang-II-mediated activation of CVOs and downstream sympathetic areas of the brain in HF, we recently tested the hypothesis that redox signaling may be an underlying mechanism in this response. Normal mice subjected to MI to induce HF exhibited hallmarks of this disorder, including increased central neural activation, shown by increased immuno-Fos staining in some cardiovascular nuclei, along with a significant increase in sympathetic output as evidenced by elevated urinary norepinephrine and pronounced cardiovascular responses to the ganglionic blocker hexamethonium (56). Interestingly, each of these indicators of excessive neurohumoral activation in the HF mice was normalized by gene transfer of AdCuZnSOD to forebrain CVOs at the time of coronary ligation (56). Furthermore, this translated into improved cardiac performance and reduced mortality rates in the HF animals (57). These results suggest that increased redox signaling in forebrain CVOs is involved in the pathogenesis of MI-induced sympathoexcitation and HF.

Since then, additional evidence has accumulated implicating NADPH oxidase as a source of ROS generation in the sympathoexcitatory loop of HF. For example, studies by Zucker and colleagues (30, 32) showed that ICV injection of apocynin, a pharmacological inhibitor of the NADPH oxidase complex, was able to both normalize ROS levels observed in the RVLM and prevent Ang-II-mediated increases in RSNA in rabbits with pacing-induced HF. Interestingly, these authors confirmed that HF rabbits also exhibited significant increases in mRNA and protein for the AT-1 receptor, as well as for subunits of the NADPH oxidase complex, including p40^{phox}, p47^{phox}, and Nox2 in RVLM (30, 31). Taken together, these experiments provide convincing evidence for NADPH oxidase-

derived ROS in abnormal CNS/Ang-II signaling that causes enhanced sympathetic activity in HF.

The ability to normalize HF-induced sympathoexcitation and improve outcomes by reducing ROS levels in the CNS, as described above, are particularly intriguing in light of recent clinical trials where treatment of chronic HF patients with a sustained-release form of moxonidine (MOXCON), a centrally-acting sympathetic inhibitor, resulted in higher mortality rates compared to HF patients given placebo (18, 77). Certainly the beneficial effects of sympathetic activation in HF, at least initially, are well documented (27, 86, 90), and the results of this trial may further support this. Although the causes of the adverse effects of MOXCON are not known, the high doses and widespread effects on sympathetic outflow to multiple end-organs may explain the excess mortality (18). In the studies described above where the redox inhibition was targeted to highly localized CNS regions of sympathetic control, it is possible that this resulted in a more specific modulation of sympathetic traffic. Indeed, although CNS gene transfer of Ad-SOD caused reductions in general markers of sympathetic tone, resting heart rate was not affected (56). In addition, it is possible that inhibition of oxidant signaling in these particular forebrain (56) and brainstem sites (31, 32) may have provided additional therapeutic effects through modulation of other neurohumoral mechanisms underlying HF (27). Clearly, a greater understanding of NADPH oxidase and other signaling pathways involved in the sympathoexcitatory loop of HF is necessary in the development of treatments for this disease.

Diversity of Nox enzymes in CNS cardiovascular circuits

While the studies described above have demonstrated primarily the involvement of Nox2 in neurocardiovascular circuits, the roles of the other Nox enzymes have not been investigated in these sites. To fully understand how NADPH oxidase is involved in neurocardiovascular disease, and to be able to target it precisely, either experimentally or therapeutically, information about the expression patterns of the Nox homologues is needed. To this end, we have recently compared the expression levels of Nox1, Nox2, and Nox4 in different regions of mouse brain using real-time PCR. We have taken this approach because of the lack of available specific antibodies. As shown in Fig. 2, Nox2 as well as Nox4 are the predominant homologues expressed in fore-, mid-, and hindbrain of mice, while Nox1 is detectable but at very low levels. Interestingly, the relative distribution of Nox2 and Nox4 differs in these regions. For example, Nox2 levels are highest in forebrain tissue, whereas Nox4 mRNA is most abundant in midbrain. Both Nox 2 and Nox 4 are expressed at nearly comparable levels in hindbrain, although Nox4 is slightly more abundant. Already this provides a hint of the complexity of this Nox family of enzymes in different brain regions. Currently we are undertaking a more specific mapping strategy to delineate Nox expression profiles in specific neurocardiovascular nuclei such as the SFO, PVN, and RVLM under normal and pathological conditions. Indeed, emerging evidence in a variety of cell types suggests that Nox transcript levels at baseline do not necessarily predict stimulus-induced activation of the enzymes, and opposing functions of various enzymes have been detected under different physiological conditions




FIG. 2. Basal levels of Nox1, Nox2, and Nox4 expression in adult C57BL/6 mouse brain estimated by quantitative real-time PCR. Summary data are presented (mean \pm SEM, $n = 3$) for Nox1, Nox2, and Nox4 transcript numbers in fore-, mid-, and hindbrain tissue. Copy numbers of Nox homologues were calculated from standard curves generated with purified plasmids. Data are expressed as copy number per 18S RNA and are for 100 ng input RNA in each sample. * $p < 0.01$ versus Nox1 and Nox4, † $p < 0.01$ versus Nox 1 and Nox2.

(36, 54, 68, 69, 74). Likewise, our preliminary studies suggest a distinct and complex distribution pattern of the homologues across these specific nuclei, with an even more elaborate profile under experimental conditions of cardiovascular disease (Infanger, Sharma, Davisson 2006 unpublished data).

These data, along with evidence presented above suggests that an increase in NADPH oxidase-derived ROS in CVOs, hypothalamic nuclei, and brainstem sites play a central role in the neurocardiovascular dysfunction observed in hypertension and HF. The expression of the Nox homologues, cytosolic regulatory subunits, and mechanisms of their activation in different brain circuits are the subject of intense ongoing investigations. Figure 3 summarizes our current knowledge of the expression profile of different NADPH oxidase components in these central pathways which utilize redox signaling mechanisms. Undoubtedly a better understanding of the expression patterns of this complex family of enzymes will spur the field forward to a greater appreciation of their function.

SUMMARY AND PERSPECTIVES

Over the past decade, an enormous amount of research has been devoted to the study of the NADPH oxidase complex in nonphagocytic cells and tissues, which has led to the identification of an entire family of Nox enzymes. While these isoforms are common in their ability to generate ROS, each is uniquely regulated and distributed, and play distinct roles in various cell types. Despite agreement about the tremendous potential importance of Nox enzymes in normal cellular functions as well as in the pathogenesis of many diseases, our knowledge about the specific mechanisms of activation and subsequent functional consequences of activating specific Nox enzymes is limited. In the CNS, NADPH oxidases are essential for diverse processes, from memory to neurocardiovascular homeostasis, and dysregulation of the enzymes result in neurodegenerative and neurogenic cardiovascular diseases. As shown in Fig. 3, multiple Nox-containing NADPH oxi-




FIG. 3. Schematic summarizing central cardiovascular regulatory pathways and identified NADPH oxidase subunits which may contribute to redox signaling in these networks. A signaling role for ROS has been established in mediating Ang-II-driven sympathoexcitation. Circulating Ang-II can interface with the CNS via blood–brain barrier lacking circumventricular organs such as the SFO, OVLT, and AP (yellow), which subsequently project to hypothalamic and hindbrain structures, including PVN, NTS, RVLM, and IML. ROS signaling is implicated in these regulatory circuits, and recently a role for NADPH has emerged in some of these nuclei. For example, Ang-II-stimulated ROS generation in the SFO depends on a Rac1/NADPH oxidase, likewise, central Ang-II stimulation increases $O_2^{\cdot-}$ and expression of NADPH oxidase subunits. Furthermore, pharmacological or peptide inhibitors of the NADPH oxidase inhibit Ang-II-stimulated neuronal firing and intracellular signaling in brainstem nuclei. Immunohistochemical staining has been used to detect subunits for which antibodies are available, and we have used real-time PCR to examine Nox homologue expression in some of these brain nuclei. NADPH oxidase subunits which have been detected or inferred are shown in color, gray shaded subunits have not been found as of yet. It is important to note multiple Nox homologues have been found in certain nuclei, suggesting multiple levels of regulation in the local oxidative environment. AP, area postrema, IML, interomedial lateral cell column of the spinal cord, MnPO, median preoptic nucleus, NTS nucleus tractus solitarius, OVLT, organum vasculosum of the lamina terminalis, PP, posterior pituitary, PVN, paraventricular nucleus, RVLM, rostral ventrolateral medulla, SFO, subfornical organ, SON, supraoptic nucleus.

dases are likely involved in the central control of cardiovascular function, and evidence is emerging that such diversity in oxidant generation applies to other CNS functions as well. Similar to peripheral organ systems, a better understanding of the expression patterns, regulation, and functional significance of specific Nox enzymes in CNS neurons and other cell types is needed.

Molecular tools to evaluate Nox function in the CNS have been relatively limited. Pharmacological and peptide inhibitors of NADPH oxidase can implicate this enzyme complex in normal or disease processes, yet the lack of selectivity necessary to unravel individual Nox homologue activation has slowed progress. Likewise, the Nox2 transgenic knockout model has been useful in studying cardiovascular physiological and pathophysiological roles of this enzyme (101, 102, 106); however, global null mutations have the potential to lead to confounding compensatory increases in expression of other Nox homologues.

In general, dissection of gene function in the mammalian brain is challenging due to the broad expression of many genes functioning in multiple neural circuits. Analysis of the molecular underpinnings of certain CNS processes, including regulation of cardiovascular function, has posed an even greater challenge because of the lack of known regulatory sequences

that restrict gene expression to specific brain nuclei (20). Recently, a number of laboratories have turned to brain site-directed gene transfer using recombinant viral vectors to circumvent this issue, and the strategy has been very useful in defining specific molecular pathways in particular circuits (20, 21, 48, 76). Coupled with conditional gene knockout using the Cre-loxP system (71, 92), and more recently gene silencing with siRNA (10, 15, 109), the potential exists for functionally mapping the roles of individual Nox enzymes and related molecules in specific CNS networks.

In addition to defining the spatiotemporal expression and activation of NADPH oxidase enzymes in the CNS under normal and pathological conditions, the cellular consequences of a chronically dysregulated oxidative environment must also be examined. It is well established that long-lasting alterations in CNS function in the setting of both physiological (*e.g.*, long-term memory) and pathophysiological (*e.g.*, neurodegeneration) processes require changes in gene expression (64, 67). A major mechanism by which this occurs is through consolidation of transient extracellular signals and activation of inducible transcription factors (2). In the context of oxidant mechanisms, redox-sensitive transcription factors such as NF- κ B and AP-1 are important proteins involved in modulating long-lasting

changes in signal transduction cascades (58) and can alter gene expression in CNS neurons (67, 70). For example, recently we and others have begun to identify ROS-dependent transcription factor activation in specific brain circuits that may be linked to long-term regulation of cardiovascular responses. Using *in vivo* bioluminescence, a technology based on photo-counting of a light-producing chemical reaction inside a living organism without the need for an excitation light (19), we have been able to track transcription factor activity in cardiovascular regulatory centers within the CNS during the pathogenesis of cardiovascular disease. Determining which transcription factors are involved in chronic manifestations of cardiovascular and other CNS-driven diseases will provide new strategies for the development of clinical treatments for these pathologies.

It is difficult to comprehend an enzyme so complexly regulated that it can function to promote cell growth and cell death, long-term potentiation and neurodegeneration, cardiovascular homeostasis and cardiovascular disease. Considering its myriad functions and diversity, it is not surprising that so little is known about the regulatory mechanisms of Nox homologues in the CNS. It is important to note that despite this broad range of functions in which it is implicated, the whole complex is still only capable of reducing molecular oxygen. This fact stresses not only the importance of Nox oxidase regulation, but also the cellular milieu in which activation takes place. Defining the consequences of an altered oxidative state in different cell types and tissues will provide essential understanding of disease pathologies and provide new treatments for these diseases. Considering the effort and progress that has been made over the past few years, such novel therapies might not be far away.

ACKNOWLEDGMENTS

Parts of this review are based on work supported by grants from the National Institutes of Health to RLD (HL-63887, HL-55006, and HL-14388) and American Heart Association (0540114N). RLD is an Established Investigator of the American Heart Association. DWI is supported by an NIH Institutional Training Grant Pre-Doctoral Fellowship (Pulmonary Training Grant, HL 07638-20, Hunninghake, GW, PI). The authors would like to thank Dennis Dunnwald and Paul Reimann for assistance with illustrations, and Dr. Matt Zimmerman for insightful suggestions and conversations throughout the writing of this review.

ABBREVIATIONS

Ang-II, angiotensin II; AP, area postrema; BBB, blood-brain barrier; CNS, central nervous system; CVO, circumventricular organ; Duox, dual oxidase; EC-SOD, extracellular superoxide dismutase; eNOS, endothelial nitric oxide synthase; ERK 1/2, extracellular signal-related protein kinase 1/2; H₂O₂, hydrogen peroxide; HF, heart failure; ICV, intracerebroventricular; iNOS, inducible nitric oxide synthase; LTP, long-term potentiation; MAPK, mitogen-activated protein kinase; MCAO, middle cerebral artery occlusion; MOXCON, moxonidine

congestive heart failure trial; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NO, nitric oxide; Nox, NADPH oxidase; Nox2, gp91^{phox}; NTS, nucleus tractus solitarius; O₂⁻, superoxide; OVLT, organum vasculosum of the lamina terminalis; PVN, paraventricular nucleus; ROS, reactive oxygen species; RVLM, rostral ventrolateral medulla; RSNA, renal sympathetic nerve activity; SFO, subfornical organ; SHR, spontaneously hypertensive rat; SOD, superoxide dismutase; WKY, Wistar-Kyoto.

REFERENCES

1. Ago T, Kitazono T, Kuroda J, Kumai Y, Kamouchi M, Ooboshi H, Wakisaka M, Kawahara T, Rokutan K, Ibayashi S, and Iida M. NAD(P)H oxidases in rat basilar arterial endothelial cells. *Stroke* 36: 1040–1046, 2005.
2. Allen RG and Tresini M. Oxidative stress and gene regulation. *Free Radic Biol Med* 28: 463–499, 2000.
3. Atkins CM and Sweatt JD. Reactive oxygen species mediate activity-dependent neuron-glia signaling in output fibers of the hippocampus. *J Neurosci* 19: 7241–7248, 1999.
4. Auerbach JM and Segal M. Peroxide modulation of slow onset potentiation in rat hippocampus. *J Neurosci* 17: 8695–8701, 1997.
5. Babior BM. NADPH oxidase. *Curr Opin Immunol* 16: 42–47, 2004.
6. Banfi B, Tirone F, Durussel I, Knisz J, Moskwa P, Molnar GZ, Krause KH, and Cox JA. Mechanism of Ca²⁺ activation of the NADPH oxidase 5 (NOX5). *J Biol Chem* 279: 18583–18591, 2004.
7. Bianca VD, Dusi S, Bianchini E, Dal PI, and Rossi F. beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. *J Biol Chem* 274: 15493–15499, 1999.
8. Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, Di Luca M, Lenzi GL, Romanelli G, Caimi L, and Padovani A. Microvascular damage and platelet abnormalities in early Alzheimer's disease. *J Neurol Sci* 203–204: 189–193, 2002.
9. Brandes RP and Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. *Cardiovasc Res* 65: 16–27, 2005.
10. Burmeister MA, Lazartigues E, Tian X, Kutschke W, Sharma RV, Kapusta DR, and Davissou RL. Virally expressed siRNA mediates localized gene silencing in specific cardiovascular (CV) regulatory nuclei of mouse brain. *FASEB J* 20: 364A. 2006.
11. Butterfield DA and Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. *Mech Ageing Dev* 122: 945–962, 2001.
12. Campese VM, Shaohua Y, and Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. *Hypertension* 46: 533–539, 2005.
13. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, and Chiu J. Reactive oxygen species stimulate central and pe-

- ripheral sympathetic nervous system activity. *Am J Physiol Heart Circ Physiol* 287: H695–H703, 2004.
14. Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, and Chan JY. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. *Circ Res* 97: 772–780, 2005.
 15. Chen Y, Chen H, Hoffmann A, Cool DR, Diz DI, Chappell MC, Chen A, and Morris M. Adenovirus-mediated small-interference RNA for *in vivo* silencing of angiotensin AT1a receptors in mouse brain. *Hypertension* 47: 230–237, 2006.
 16. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. *Gene* 269: 131–140, 2001.
 17. Choi SH, Lee dY, Kim SU, and Jin BK. Thrombin-induced oxidative stress contributes to the death of hippocampal neurons *in vivo*: role of microglial NADPH oxidase. *J Neurosci* 25: 4082–4090, 2005.
 18. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, and Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *Eur J Heart Fail* 5: 659–667, 2003.
 19. Contag PR, Olomu IN, Stevenson DK, and Contag CH. Bioluminescent indicators in living mammals. *Nat Med* 4: 245–247, 1998.
 20. Davisson RL. Physiological genomic analysis of the brain renin-angiotensin system. *Am J Physiol Regul Integr Comp Physiol* 285: R498–R511, 2003.
 21. de Lima MC, da Cruz MT, Cardoso AL, Simoes S, and de Almeida LP. Liposomal and viral vectors for gene therapy of the central nervous system. *Curr Drug Targets CNS Neurol Disord* 4: 453–465, 2005.
 22. DiBona GF. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. *J Am Soc Nephrol* 10 Suppl 11: S90–S94, 1999.
 23. DiBona GF, Jones SY, and Brooks VL. ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. *Am J Physiol* 269: R1189–R1196, 1995.
 24. Dringen R. Oxidative and antioxidative potential of brain microglial cells. *Antioxid Redox Signal* 7: 1223–1233, 2005.
 25. Edgley A, Kett M, and Anderson W. ‘Slow pressor’ hypertension from low-dose chronic angiotensin II infusion. *Clin Exp Pharmacol Physiol* 28: 1035–1039, 2001.
 26. Esler M. The sympathetic system and hypertension. *Am J Hypertens* 13: 99S–105S, 2000.
 27. Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, and Johnson AK. Heart failure and the brain: new perspectives. *Am J Physiol Regul Integr Comp Physiol* 284: R259–R276, 2003.
 28. Gao HM, Liu B, and Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. *J Neurosci* 23: 6181–6187, 2003.
 29. Gao HM, Liu B, Zhang W, and Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the *in vitro* MPTP model of Parkinson’s disease. *FASEB J* 17: 1954–1956, 2003.
 30. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, and Zucker IH. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. *Circ Res* 95: 937–944, 2004.
 31. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, and Zucker IH. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. *Circulation* 112: 1763–1770, 2005.
 32. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, and Zucker IH. Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. *Am J Physiol Heart Circ Physiol* 288: H2271–H2279, 2005.
 33. Giasson BI, Ischiropoulos H, Lee VM, and Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases. *Free Radic Biol Med* 32: 1264–1275, 2002.
 34. Green SP, Cairns B, Rae J, Errett-Baroncini C, Hongo JA, Erickson RW, and Curnutte JT. Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation. *J Cereb Blood Flow Metab* 21: 374–384, 2001.
 35. Gregg D, Rauscher FM, and Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. *Am J Physiol Cell Physiol* 285: C723–C734, 2003.
 36. Griendling KK. Novel NAD(P)H oxidases in the cardiovascular system. *Heart* 90: 491–493, 2004.
 37. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res* 74: 1141–1148, 1994.
 38. Groemping Y and Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. *Biochem J* 386: 401–416, 2005.
 39. Head GA. Role of AT1 receptors in the central control of sympathetic vasomotor function. *Clin Exp Pharmacol Physiol Suppl* 3: S93–S98, 1996.
 40. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, and Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. *Nature* 377: 239–242, 1995.
 41. Ishikawa M, Stokes KY, Zhang JH, Nanda A, and Granger DN. Cerebral microvascular responses to hypercholesterolemia: roles of NADPH oxidase and P-selectin. *Circ Res* 94: 239–244, 2004.
 42. Jana A and Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer’s disease. *J Biol Chem* 279: 51451–51459, 2004.
 43. Jenner P and Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. *Neurology* 47: S161–S170, 1996.
 44. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, and Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. *Circ Res* 95: 1019–1026, 2004.

45. Kenney MJ, Weiss ML, and Haywood JR. The paraventricular nucleus: an important component of the central neurocircuitry regulating sympathetic nerve outflow. *Acta Physiol Scand* 177: 7–15, 2003.
46. Kim MJ, Shin KS, Chung YB, Jung KW, Cha CI, and Shin DH. Immunohistochemical study of p47Phox and gp91Phox distributions in rat brain. *Brain Res* 1040: 178–186, 2005.
47. Kimura Y, Hirooka Y, Sagara Y, Ito K, Kishi T, Shimokawa H, Takeshita A, and Sunagawa K. Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress. *Circ Res* 96: 252–260, 2005.
48. Kirik D and Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. *Trends Neurosci* 26: 386–392, 2003.
49. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, and Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. *Circulation* 109: 2357–2362, 2004.
50. Klein JA and Ackerman SL. Oxidative stress, cell cycle, and neurodegeneration. *J Clin Invest* 111: 785–793, 2003.
51. Kontos HA. Oxygen radicals in cerebral ischemia: the 2001 Willis lecture. *Stroke* 32: 2712–2716, 2001.
52. Kusaka I, Kusaka G, Zhou C, Ishikawa M, Nanda A, Granger DN, Zhang JH, and Tang J. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. *Am J Physiol Heart Circ Physiol* 286: H2442–H2451, 2004.
53. Lambeth JD. NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol* 4: 181–189, 2004.
54. Lassegue B and Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. *Am J Physiol Regul Integr Comp Physiol* 285: R277–R297, 2003.
55. Lavigne MC, Malech HL, Holland SM, and Leto TL. Genetic requirement of p47phox for superoxide production by murine microglia. *FASEB J* 15: 285–287, 2001.
56. Lindley TE, Doobay MF, Sharma RV, and Davissan RL. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. *Circ Res* 94: 402–409, 2004.
57. Lindley TE, Sharma RV, and Davissan RL. Increased superoxide scavenging in the brain improves survival and cardiac performance following myocardial infarction. *Hypertension* 42: 390, 2003.
58. Liu H, Colavitti R, Rovira II, and Finkel T. Redox-dependent transcriptional regulation. *Circ Res* 97: 967–974, 2005.
59. Lu N, Helwig BG, Fels RJ, Parimi S, and Kenney MJ. Central Tempol alters basal sympathetic nerve discharge and attenuates sympathetic excitation to central ANG II. *Am J Physiol Heart Circ Physiol* 287: H2626–H2633, 2004.
60. Mander P and Brown GC. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. *J Neuroinflammation* 2: 20, 2005.
61. Mangiapane ML and Simpson JB. Subfornical organ: forebrain site of pressor and dipsogenic action of angiotensin II. *Am J Physiol* 239: R382–R389, 1980.
62. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. *Cell Signal* 18: 69–82, 2006.
63. Maru Y, Nishino T, and Kakinuma K. Expression of Nox genes in rat organs, mouse oocytes, and sea urchin eggs. *DNA Seq* 16: 83–88, 2005.
64. Mattson MP and Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. *J Clin Invest* 107: 247–254, 2001.
65. Mayorov DN, Head GA, and De Matteo R. Tempol attenuates excitatory actions of angiotensin II in the rostral ventrolateral medulla during emotional stress. *Hypertension* 44: 101–106, 2004.
66. McKinley MJ, Allen AM, May CN, McAllen RM, Oldfield BJ, Sly D, and Mendelsohn FA. Neural pathways from the lamina terminalis influencing cardiovascular and body fluid homeostasis. *Clin Exp Pharmacol Physiol* 28: 990–992, 2001.
67. Meffert MK and Baltimore D. Physiological functions for brain NF-kappaB. *Trends Neurosci* 28: 37–43, 2005.
68. Miller AA, Drummond GR, Schmidt HH, and Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. *Circ Res* 97: 1055–1062, 2005.
69. Mitsuhashi J, Lambeth JD, and Kamata T. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. *Cancer Res* 64: 3580–3585, 2004.
70. Morgan JI and Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. *Annu Rev Neurosci* 14: 421–451, 1991.
71. Morozov A, Kellendonk C, Simpson E, and Tronche F. Using conditional mutagenesis to study the brain. *Biol Psychiatry* 54: 1125–1133, 2003.
72. Norris EH and Giasson BI. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. *Antioxid Redox Signal* 7: 672–684, 2005.
73. Olanow CW and Tatton WG. Etiology and pathogenesis of Parkinson's disease. *Annu Rev Neurosci* 22: 123–144, 1999.
74. Paravicini TM, Drummond GR, and Sobey CG. Reactive oxygen species in the cerebral circulation: physiological roles and therapeutic implications for hypertension and stroke. *Drugs* 64: 2143–2157, 2004.
75. Patel M, Li QY, Chang LY, Crapo J, and Liang LP. Activation of NADPH oxidase and extracellular superoxide production in seizure-induced hippocampal damage. *J Neurochem* 92: 123–131, 2005.
76. Paton JF, Boscan P, Murphy D, and Kasparov S. Unraveling mechanisms of action of angiotensin II on cardiorespiratory function using *in vivo* gene transfer. *Acta Physiol Scand* 173: 127–137, 2001.
77. Pocock S, Wilhelmssen L, Dickstein K, Francis G, and Wittes J. The data monitoring experience in the MOXCON trial. *Eur Heart J* 25: 1974–1978, 2004.

78. Prescott G, Silversides DW, Chiu SM, and Reudelhuber TL. Contribution of circulating renin to local synthesis of angiotensin peptides in the heart. *Physiol Genomics* 4: 67–73, 2000.
79. Rahmouni K, Correia ML, Haynes WG, and Mark AL. Obesity-associated hypertension: new insights into mechanisms. *Hypertension* 45: 9–14, 2005.
80. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griending KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest* 97: 1916–1923, 1996.
81. Ray R and Shah AM. NADPH oxidase and endothelial cell function. *Clin Sci (Lond)* 109: 217–226, 2005.
82. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. *Circ Res* 89: 408–414, 2001.
83. Sakai K and Sigmund CD. Molecular evidence of tissue renin-angiotensin systems: a focus on the brain. *Curr Hypertens Rep* 7: 135–140, 2005.
84. Sankarapandi S, Zweier JL, Mukherjee G, Quinn MT, and Huso DL. Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. *Arch Biochem Biophys* 353: 312–321, 1998.
85. Sayre LM, Smith MA, and Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. *Curr Med Chem* 8: 721–738, 2001.
86. Schrier RW and Abraham WT. Hormones and hemodynamics in heart failure. *N Engl J Med* 341: 577–585, 1999.
87. Sellers KW, Sun C, Diez-Freire C, Waki H, Morisseau C, Falck JR, Hammock BD, Paton JF, and Raizada MK. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. *FASEB J* 19: 626–628, 2005.
88. Serrano F, Kolluri NS, Wientjes FB, Card JP, and Klann E. NADPH oxidase immunoreactivity in the mouse brain. *Brain Res* 988: 193–198, 2003.
89. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, and Fujimoto S. Activation of NADPH oxidase in Alzheimer's disease brains. *Biochem Biophys Res Commun* 273: 5–9, 2000.
90. Sigurdsson A and Swedberg K. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. *Am Heart J* 132: 229–234, 1996.
91. Sinnayah P, Lindley TE, Staber PD, Cassell MD, Davidson BL, and Davisson RL. Selective gene transfer to key cardiovascular regions of the brain: comparison of two viral vector systems. *Hypertension* 39: 603–608, 2002.
92. Sinnayah P, Lindley TE, Staber PD, Davidson BL, Cassell MD, and Davisson RL. Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain. *Physiol Genomics* 18: 25–32, 2004.
93. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griending KK, and Lambeth JD. Cell trans-formation by the superoxide-generating oxidase Mox1. *Nature* 401: 79–82, 1999.
94. Sun C, Sellers KW, Summers C, and Raizada MK. NAD(P)H oxidase inhibition attenuates neuronal chronotropic actions of angiotensin II. *Circ Res* 96: 659–666, 2005.
95. Tagawa T, Fontes MA, Potts PD, Allen AM, and Dampney RA. The physiological role of AT1 receptors in the ventrolateral medulla. *Braz J Med Biol Res* 33: 643–652, 2000.
96. Tai MH, Hsiao M, Chan JY, Lo WC, Wang FS, Liu GS, Howng SL, and Tseng CJ. Gene delivery of endothelial nitric oxide synthase into nucleus tractus solitarius induces biphasic response in cardiovascular functions of hypertensive rats. *Am J Hypertens* 17: 63–70, 2004.
97. Tai MH, Wang LL, Wu KL, and Chan JY. Increased superoxide anion in rostral ventrolateral medulla contributes to hypertension in spontaneously hypertensive rats via interactions with nitric oxide. *Free Radic Biol Med* 38: 450–462, 2005.
98. Tammariello SP, Quinn MT, and Estus S. NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. *J Neurosci* 20: RC53, 2000.
99. Tejada-Simon MV, Serrano F, Villasana LE, Kanterewicz BI, Wu GY, Quinn MT, and Klann E. Synaptic localization of a functional NADPH oxidase in the mouse hippocampus. *Mol Cell Neurosci* 29: 97–106, 2005.
100. Thiels E, Urban NN, Gonzalez-Burgos GR, Kanterewicz BI, Barrionuevo G, Chu CT, Oury TD, and Klann E. Impairment of long-term potentiation and associative memory in mice that overexpress extracellular superoxide dismutase. *J Neurosci* 20: 7631–7639, 2000.
101. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, and Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. *Circulation* 111: 2347–2355, 2005.
102. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, and Reudelhuber TL. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. *Hypertension* 45: 530–537, 2005.
103. Vallet P, Charnay Y, Steger K, Ogier-Denis E, Kovari E, Herrmann F, Michel JP, and Szanto I. Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia. *Neuroscience* 132: 233–238, 2005.
104. Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Dinauer MC, Curnutte JT, and Thomas GR. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. *Stroke* 28: 2252–2258, 1997.
105. Wang G, Anrather J, Huang J, Speth RC, Pickel VM, and Iadecola C. NADPH oxidase contributes to angiotensin II signaling in the nucleus tractus solitarius. *J Neurosci* 24: 5516–5524, 2004.
106. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, and Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. *Circ Res* 88: 947–953, 2001.
107. Wang W and Ma R. Cardiac sympathetic afferent reflexes in heart failure. *Heart Fail Rev* 5: 57–71, 2000.

108. Weiss ML, Kenney MJ, Musch TI, and Patel KP. Modifications to central neural circuitry during heart failure. *Acta Physiol Scand* 177: 57–67, 2003.
109. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, and Davidson BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. *Nat Med* 10: 816–820, 2004.
110. Xie H, Ray PE, and Short BL. NF-kappaB activation plays a role in superoxide-mediated cerebral endothelial dysfunction after hypoxia/reoxygenation. *Stroke* 36: 1047–1052, 2005.
111. Zanzinger J. Mechanisms of action of nitric oxide in the brain stem: role of oxidative stress. *Auton Neurosci* 98: 24–27, 2002.
112. Zanzinger J and Czachurski J. Chronic oxidative stress in the RVLM modulates sympathetic control of circulation in pigs. *Pflugers Arch* 439: 489–494, 2000.
113. Zekry D, Epperson TK, and Krause KH. A role for NOX NADPH oxidases in Alzheimer's disease and other types of dementia? *IUBMB Life* 55: 307–313, 2003.
114. Zhan G, Serrano F, Fenik P, Hsu R, Kong L, Pratico D, Klann E, and Veasey SC. NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. *Am J Respir Crit Care Med* 172: 921–929, 2005.
115. Zhang W, Huang BS, and Leenen FH. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. *Am J Physiol* 276: H1608–H1615, 1999.
116. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Zhang W, Hong JS, and Liu B. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. *FASEB J* 18: 589–591, 2004.
117. Zhu GQ, Gao L, Li Y, Patel KP, Zucker IH, and Wang W. AT1 receptor mRNA antisense normalizes enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. *Am J Physiol Heart Circ Physiol* 287: H1828–H1835, 2004.
118. Zimmerman MC and Davisson RL. Redox signaling in central neural regulation of cardiovascular function. *Prog Biophys Mol Biol* 84: 125–149, 2004.
119. Zimmerman MC, Dunlay RP, Lazartigues E, Zhang Y, Sharma RV, Engelhardt JF, and Davisson RL. Requirement for Rac1-dependent NADPH oxidase in the cardiovascular and dipsogenic actions of angiotensin II in the brain. *Circ Res* 95: 532–539, 2004.
120. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, and Davisson RL. Superoxide mediates the actions of angiotensin II in the central nervous system. *Circ Res* 91: 1038–1045, 2002.
121. Zimmerman MC, Lazartigues E, Sharma RV, and Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. *Circ Res* 95: 210–216, 2004.
122. Zimmerman MC, Sharma RV, and Davisson RL. Superoxide mediates angiotensin II-induced influx of extracellular calcium in neural cells. *Hypertension* 45: 717–723, 2005.
123. Zucker IH, Schultz HD, Li YF, Wang Y, Wang W, and Patel KP. The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide. *Prog Biophys Mol Biol* 84: 217–232, 2004.

Address reprint requests to:

Robin L. Davisson, Ph.D.

Anatomy and Cell Biology

1-251 Bowen Science Building

The Roy J. and Lucille A. Carver College of Medicine

The University of Iowa

Iowa City, IA 52245

E-mail: robin-davisson@uiowa.edu

Date of first submission to ARS Central, April 24, 2006; date of acceptance, April 26, 2006.